GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » EV-to-EBITDA

Mycenax Biotech (ROCO:4726) EV-to-EBITDA : -62.19 (As of Jun. 02, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mycenax Biotech's enterprise value is NT$8,477.3 Mil. Mycenax Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-136.3 Mil. Therefore, Mycenax Biotech's EV-to-EBITDA for today is -62.19.

The historical rank and industry rank for Mycenax Biotech's EV-to-EBITDA or its related term are showing as below:

ROCO:4726' s EV-to-EBITDA Range Over the Past 10 Years
Min: -456   Med: -19.38   Max: 4032.67
Current: -62.19

During the past 13 years, the highest EV-to-EBITDA of Mycenax Biotech was 4032.67. The lowest was -456.00. And the median was -19.38.

ROCO:4726's EV-to-EBITDA is ranked worse than
100% of 493 companies
in the Biotechnology industry
Industry Median: 8.55 vs ROCO:4726: -62.19

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-02), Mycenax Biotech's stock price is NT$37.40. Mycenax Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was NT$-2.230. Therefore, Mycenax Biotech's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Mycenax Biotech EV-to-EBITDA Historical Data

The historical data trend for Mycenax Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech EV-to-EBITDA Chart

Mycenax Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.29 75.58 -45.40 -21.64 -70.28

Mycenax Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.17 -75.31 -56.17 -70.28 -60.48

Competitive Comparison of Mycenax Biotech's EV-to-EBITDA

For the Biotechnology subindustry, Mycenax Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's EV-to-EBITDA falls into.


;
;

Mycenax Biotech EV-to-EBITDA Calculation

Mycenax Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=8477.295/-136.319
=-62.19

Mycenax Biotech's current Enterprise Value is NT$8,477.3 Mil.
Mycenax Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-136.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mycenax Biotech  (ROCO:4726) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Mycenax Biotech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=37.40/-2.230
=At Loss

Mycenax Biotech's share price for today is NT$37.40.
Mycenax Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-2.230.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Mycenax Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines